Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

product recall

Teva Pharma logo

Teva hit with $1.2bn pay-for-delay fine

Federal Trade Commission continues its tough stance against generic blocking

Teva Pharma logo

Teva says chronic migraine drug is ready for phase III

TEV-48125 efficacy “has not previously been achieved”

- PMLiVE

Perrigo rejects Mylan again as Teva bites back

There is much debate over the value of the company’s shares

- PMLiVE

Mylan pulls no punches in rejecting Teva takeover

Firm calls Israeli generics giant’s credibility into question

- PMLiVE

Teva circling as Perrigo rejects second Mylan offer

Claims latest offer is lower than a recent informal bid

- PMLiVE

Teva offers $40bn for Mylan as Perrigo backs away

Generic drug industry could be shaken up if deals go through

Teva Pharma logo

Teva slapped with $512m fine on pay-for-delay deal

Israeli firm pays out to settle claims it hindered use of generic Provigil

- PMLiVE

Rise of generics will curb France’s pharma growth

Generics are set to take a serious bite out of the market as a cash-strapped government pushes for cost controls

France flag

France health reforms draw opposition from doctors

Doctors claim the changes will leave them out of pocket

Teva Pharma logo

Teva starts M&A push with $3.5bn Auspex buy

Aims to diversify business away from dependency on Copaxone

Teva appoints Timothy Wright as business development head

The former Covidien Pharma president mostrecently led a US cancer centre

France flag

French pharma growth restricted by generics

New analysis finds country’s market value will grow only modestly in the coming years

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links